DUSA Pharmaceuticals, Inc.

DUSA Pharmaceuticals, Inc.® is an integrated dermatology pharmaceutical company committed to improving people's health and confidence through its quality dermatological treatments. DUSA markets and continues to develop its Levulan® Photodynamic Therapy (PDT) technology platform, which is a treatment for the pre-cancerous skin lesions known as Actinic Keratoses (AK). DUSA is also developing certain internal indications of Levulan PDT.

DUSA's portfolio of complementary dermatology products includes ClindaReach®, which was acquired from Sirius Laboratories, Inc. ClindaReach is a topical acne treatment which includes a novel applicator for those hard-to-reach areas.